Intravenous istaroxime for the treatment of acute heart failure
AssigneeSeismic Pharmaceuticals Operations LLC
InventorsGiuseppe Bianchi, Patrizia Ferrari, Mara Ferrandi, Paolo Barassi
Life of this patent
Estimating the term…
Abstract
Described herein are methods of treating acute heart failure in a subject in need thereof, comprising administering a therapeutically effective amount of istaroxime by intravenous infusion over a period of at least 24 hours wherein the therapeutically effective amount of istaroxime is between about 0.1 μg/kg/min and about 3.0 g/kg/min; and wherein the subject's acute heart failure is treated.
Claims19
A method of treating acute heart failure in a subject in need thereof, comprising administering a therapeutically effective amount of istaroxime by intravenous infusion over a period of at least 24 hours, wherein the therapeutically effective amount of istaroxime is between about 0.1 μg/kg/min and about 3.0 μg/kg/min, wherein administering a therapeutically effective amount of istaroxime does not result in a significant change in at least one of heart rate, myocardial energy consumption, brain natriuretic peptide (BNP) levels, N-terminal pro BNP (NT-proBNP) levels, and cardiac troponin levels, thereby treating the subject's acute heart failure.
Dependencies are inferred from the claim text.